10/27
09:06 am
enta
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]
Low
Report
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]
10/10
08:40 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
10/9
02:40 pm
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
10/2
09:47 am
enta
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]
9/27
11:05 am
enta
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
Medium
Report
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.
9/26
06:00 am
enta
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Low
Report
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
9/3
07:00 am
enta
Enanta Pharmaceuticals to Participate in Investor Conferences in September
Low
Report
Enanta Pharmaceuticals to Participate in Investor Conferences in September